Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on March 4, 2016, covering events occurring on March 1 and March 2, 2016. The filing details modifications to the compensatory arrangements of the Company's executive officers following an annual review by the Compensation Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Board of Directors approved the following changes to executive compensation, effective January 1, 2016:
- Jack A. Khattar (CEO): Base salary increased from $525,000 to $596,000. Received a 2015 bonus of $362,000 and options for 255,000 shares. The 2016 bonus target increased to 70% of base salary (from 60%). An amendment to his employment agreement eliminated the provision limiting the target bonus.
- Gregory S. Patrick (CFO): Base salary increased from $331,000 to $341,000. Received a 2015 bonus of $141,000 and options for 50,000 shares. The 2016 bonus target remains at 40% of base salary.
- Stefan K.F. Schwabe (CMO): Base salary increased from $357,000 to $367,000. Received a 2015 bonus of $151,000 and options for 50,000 shares. The 2016 bonus target remains at 40% of base salary.
- Padmanabh P. Bhatt (CSO): Base salary increased from $338,000 to $348,000. Received a 2015 bonus of $110,000 and options for 40,000 shares. The 2016 bonus target increased to 35% of base salary (from 30%).
- Victor L. Vaughn (SVP Sales): Base salary increased from $292,000 to $321,000. Received a 2015 bonus of $110,000 and options for 50,000 shares. The 2016 bonus target increased to 40% of base salary (from 35%).
All stock option grants have an exercise price of $12.98 per share, based on the closing price on March 1, 2016. Vesting occurs annually in equal increments over four years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The compensation changes were recommended by Radford, the Company's independent compensation consulting firm, to align with industry peer groups. No specific risks or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the total annualized cost increase to the Company resulting from the base salary adjustments for all five executives.
- Review the full text of Exhibit 10.1 (Second Amendment to Employment Agreement) to understand the specific terms regarding the removal of the bonus cap for the CEO.
- Confirm the dilution impact of the 445,000 total new stock options granted to executives.
- Assess whether the increased bonus targets (particularly for the CEO and SVP of Sales) align with the Company's current financial performance and future revenue projections.